Literature DB >> 22988005

Behavioral and emotional symptoms and primary headaches in children: a population-based study.

Marco A Arruda1, Marcelo E Bigal.   

Abstract

OBJECTIVE: To investigate behavioral and emotional symptoms in a community-based sample of children as a function of headache status and of headache frequency.
METHODS: Our sample consisted of 1,856 children (5-11 years). Primary headaches were assessed using a validated headache questionnaire. Emotional symptoms were assessed by the Child Behavior Checklist (CBCL). CBCL scores were modeled as a function of headache status after adjustments for demographics and headache frequency.
RESULTS: Relative to controls, children with migraine were significantly more likely to have abnormalities in the following CBCL domains: somatic, anxiety-depressive, social, attention, internalizing and total score. Children with tension-type headache (TTH) were significantly different from controls in the same domains but at a lower rate than migraine. In children with migraine, impairments significantly varied as a function of headache frequency, race, and income. In children with TTH, gender, age, and headache frequency were significantly associated with abnormal scores.
CONCLUSIONS: Migraine and TTH are significantly associated with behavioral symptoms in several domains, and headache frequency affects the association. Internalizing symptoms are common in children with headaches, while externalizing symptoms (e.g. rule-breaking and aggressivity) are not significantly more common than in controls.

Entities:  

Mesh:

Year:  2012        PMID: 22988005     DOI: 10.1177/0333102412454226

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  18 in total

Review 1.  Headache in school children: prevalence and risk factors.

Authors:  Andreas Straube; Florian Heinen; Friedrich Ebinger; Rüdiger von Kries
Journal:  Dtsch Arztebl Int       Date:  2013-11-29       Impact factor: 5.594

2.  A pilot educational intervention for headache and concussion: The headache and arts program.

Authors:  Mia T Minen; Alexandra Boubour
Journal:  Neurology       Date:  2018-04-13       Impact factor: 9.910

Review 3.  Headache in school children: is the prevalence increasing?

Authors:  Lucia Albers; Rüdiger von Kries; Florian Heinen; Andreas Straube
Journal:  Curr Pain Headache Rep       Date:  2015-03

4.  Comorbidity of Migraine, Major Depressive Disorder, and Generalized Anxiety Disorder in Adolescents and Young Adults.

Authors:  Lilian N Dindo; Ana Recober; Rita Haddad; Chadi A Calarge
Journal:  Int J Behav Med       Date:  2017-08

Review 5.  Zolmitriptan Nasal Spray: A Review in Acute Migraine in Pediatric Patients 12 Years of Age or Older.

Authors:  Kate McKeage
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.022

Review 6.  Pediatric Aspects of Headache Classification in the International Classification of Headache Disorders-3 (ICHD-3 beta version).

Authors:  Gary N McAbee; Anne Marie Morse; Mitra Assadi
Journal:  Curr Pain Headache Rep       Date:  2016-01

Review 7.  Epidemiology of migraine and headache in children and adolescents.

Authors:  Ciçek Wöber-Bingöl
Journal:  Curr Pain Headache Rep       Date:  2013-06

Review 8.  Pharmacological treatment of acute migraine in adolescents and children.

Authors:  Çiçek Wöber-Bingöl
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

9.  Psychotherapy versus usual care in pediatric migraine and tension-type headache: a single-blind controlled pilot study.

Authors:  Umberto Balottin; Matteo Ferri; Michela Racca; Maura Rossi; Giorgio Rossi; Ettore Beghi; Matteo Chiappedi; Cristiano Termine
Journal:  Ital J Pediatr       Date:  2014-01-20       Impact factor: 2.638

10.  Maternal personality profile of children affected by migraine.

Authors:  Maria Esposito; Michele Roccella; Beatrice Gallai; Lucia Parisi; Serena Marianna Lavano; Rosa Marotta; Marco Carotenuto
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-11       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.